Literature DB >> 8742127

Growth hormone axis in cushing's syndrome.

B L Wajchenberg1, B Liberman, D Giannella Neto, M Y Morozimato, M Semer, L O Bracco, L R Salgado, M Knoepfelmacher, M H Borges, A C Pinto, C E Kater, A M Lengyel.   

Abstract

All levels of the growth hormone (GH), GH binding protein (GHBP), insulin-like growth factor (IGF) and IGF binding protein (IGFBP) axis are influenced by chronic hypercortisolism. Thus, there is a blunted response to GHRH alone or together with other stimuli associated with a marked suppression of endogenous GH secretion but accompanied by normal GHBP, normal to low IGF-1 and GHBPs 1 and 3 with the correspondent 41.5 and 38.5-kD molecular forms of the latter presenting values similar to normal. These findings may suggest enhanced GH sensitivity with normal or increased IGF-1 bioavailability to the correspondent tissue receptors. In conclusion, the glucocorticoid (GC)-induced target tissue resistance can neither be attributed to the suppression of the GH axis nor to changes in circulating GHBPs 1 and 3. However, it may be related either to the described 12-to-20-kD inhibitor(s) which antagonizes postbinding IGF-1 bioactivity (gene expression) and/or by the downmodulation of activator protein-1 (Fos/Jun) activity by the GC-GC receptor complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8742127     DOI: 10.1159/000184767

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  12 in total

1.  [Molecular analysis of the human "growth hormone secretagogue"-receptor].

Authors:  S Petersenn; M Penshorn; F U Beil; H M Schulte
Journal:  Med Klin (Munich)       Date:  1999-04-15

2.  Use of desmopressin as an alternative to corticotropin-releasing hormone during inferior petrosal sinus sampling in a child with Cushing's disease.

Authors:  M H Gannagé-Yared; S Slaba; T Rizk; R-M Chidiac Wehbe
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

3.  Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH.

Authors:  F E Finamor; A M Lengyel
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

Review 4.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

5.  IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

Authors:  M H Borges; A C Pinto; F B DiNinno; C Camacho-Hübner; A Grossman; C E Kater; A M Lengyel
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

6.  Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.

Authors:  L Gianotti; J Ramunni; F Lanfranco; B Maccagno; R Giordano; F Broglio; M Maccario; E E Muller; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

Review 7.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

8.  Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.

Authors:  Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov
Journal:  Osteoporos Int       Date:  2013-01-29       Impact factor: 4.507

9.  The unexpected anabolic phenotype and extended longevity of skin fibroblasts after chronic glucocorticoid excess.

Authors:  Harris Pratsinis; Stylianos Tsagarakis; Irene Zervolea; Dimitri Stathakos; Nikos Thalassinos; Dimitris Kletsas
Journal:  Dose Response       Date:  2006-08-19       Impact factor: 2.658

Review 10.  IGF-I measurements in the diagnosis of adult growth hormone deficiency.

Authors:  Anita Y M Kwan; Mark L Hartman
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.